Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

MDX-210 demonstrates antitumor activity in phase II studies

Dec. 4, 1998

Vical provides clinical update of Leuvectin in treatment of prostate cancer

Dec. 2, 1998

Neurocrine Biosciences advances development of NBI-3001

Nov. 30, 1998

Cell Genesys broadens GVAX trials program in prostate cancer

Nov. 30, 1998

B43-PAP: a promising treatment for Ph+ ALL in development at Hughes Institute

Nov. 30, 1998

PEG-Intron A advances to phase III trials for chronic myelogenous leukemia

Nov. 25, 1998

Novopharm Biotech completes patient enrollment for phase I study of NOVOMAb-G2

Nov. 23, 1998

New U.S. patent provides protection for improved Avicine formulations

Nov. 20, 1998

Vical provides clinical update of Allovectin-7 in treatment of head and neck cancer

Nov. 18, 1998

Study shows Zadaxin plus chemotherapy inhibits cancerous tumors in mice

Nov. 18, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...